Kevin Feeley sold $1.3M of WGS
CHIEF FINANCIAL OFFICER at GeneDx Holdings Corp.. 14,270 shares at an average of $92.06, traded Apr 9, 2025, filed May 9, 2025.
Score components
- +22RoleCFO
- +25Trade size$1.3M at market
- +20Share of holdings soldSold 83% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-012579, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 9, 2025 | MOption exercise Class A Common Stock10b5-1 | +1,246 | $32.67 | $41k | 17,242 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -637 | $83.67 | $53k | 16,605 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,198 | $84.61 | $101k | 15,407 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,171 | $85.73 | $100k | 14,236 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -249 | $86.48 | $22k | 13,987 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -5,993 | $93.28 | $559k | 7,994 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -2,693 | $94.61 | $255k | 5,301 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,463 | $95.53 | $140k | 3,838 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -846 | $96.46 | $82k | 2,992 | May 9, 2025 |
| Apr 9, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -20 | $97.26 | $1,945 | 2,972 | May 9, 2025 |
| Apr 9, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -1,246 | $0.00 | $0 | 7,473 | May 9, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 39Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $557k 8,818 shares | -20% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $3.0M 46,933 shares | -34% | |
| 37Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $438k 5,706 shares | -17% | |
| 48Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.3M 17,179 shares | -23% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $111k 1,280 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.